HIV: key endpoint results by drug

The key endpoints of HIV trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the HIV page.

HIV-1 RNA below 50 copies/mL (week 48) (maintenance)

HIV-1 RNA below 50 copies/mL (week 48) in HIV: 12 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Bictegravir92.4%93% (ABC/DTG/3TC)—wk 48 · n 314NCT02607930 Phase 3, primary
Cabotegravir/rilpivirine (Cabenuva)94%91% (CAB 30 mg+ABC/3TC)—IM-Q4W · wk 32 · n 115NCT02120352 Phase 2, primary
Dolutegravir88%85% (RTG)—50 mg Once a Day · wk 48 · n 411NCT01227824 Phase 3, primary
Doravirine83.8%79.9% (Daurunavir + Ritonavir)—100 mg · wk 48 · n 383NCT02275780 Phase 3, primary
Elvitegravir87.6%84.1% (Atripla)—wk 48 · n 348NCT01095796 Phase 3, primary
Emtricitabine/tenofovir disoproxil fumarate83.8%79.9% (Daurunavir + Ritonavir)—100 mg · wk 48 · n 383NCT02275780 Phase 3, primary
Etravirine56%a39%+17wk 24NCT00254046 Phase 3, primary
Fostemsavir72%75% (ATV/r)—1200 mg QD · wk 24 · n 50NCT01384734 Phase 2, primary
Lenacapavir (Sunlenca)90.4%92% (B/F/TAF)—wk 54 · n 52NCT04143594 Phase 2, primary
Maraviroc41.8%16.1%+25.7QD · wk 48 · n 232NCT00098306 Phase 2/3, secondary
Rilpivirine94%94% (CAR)—DTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797 Phase 3, primary
Tenofovir alafenamide/emtricitabine94.3%93% (FTC/TDF)—wk 48 · n 333NCT02121795 Phase 3, primary

Drugs checked with no result here: 9 not posted, 9 not reported, 11 trial running.

HIV-1 RNA 50 copies/mL or more (week 48) (maintenance)

HIV-1 RNA 50 copies/mL or more (week 48) in HIV: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Bictegravir0.4%1.1% (DTG + F/TAF)—wk 48 · n 284NCT03110380 Phase 3, primary
Cabotegravir/rilpivirine (Cabenuva)0%0% (DTG + RPV)—Q2M · wk 48 · n 90NCT03639311 Phase 2, primary
Doravirine0%1.5% (Baseline Antiretroviral Therapy (ART))—wk 48 · n 336NCT04223778 Phase 3, primary
Rilpivirine0.6%0% (FTC/RPV/TDF)—wk 48 · n 316NCT02345252 Phase 3, secondary
Tenofovir alafenamide/emtricitabine0.4%1.1% (DTG + F/TAF)—wk 48 · n 284NCT03110380 Phase 3, primary

Drugs checked with no result here: 12 not posted, 11 not reported, 13 trial running.

CD4 count, change (week 48) (maintenance)

CD4 count, change (week 48) in HIV: 14 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Bictegravir180201 (DTG + F/TAF)—wk 48 · n 290NCT02607956 Phase 3, secondary
Cabotegravir/rilpivirine (Cabenuva)263.7346.1 (CAB 30 mg+ABC/3TC)—IM-Q4W · wk 32 · n 108NCT02120352 Phase 2, secondary
Darunavir541 (SBR)—wk 48 · n 85NCT01968551 Phase 3, secondary
Dolutegravir115156−4150 mg BID · wk 48 · n 14NCT01568892 Phase 3, secondary
Doravirine192.7185.6 (Daurunavir + Ritonavir)—100 mg · wk 48 · n 363NCT02275780 Phase 3, secondary
Elvitegravir239206 (Atripla)—wk 48 · n 348NCT01095796 Phase 3, secondary
Emtricitabine/tenofovir disoproxil fumarate192.7185.6 (Daurunavir + Ritonavir)—100 mg · wk 48 · n 363NCT02275780 Phase 3, secondary
Fostemsavir155.4178.7 (ATV/r)—1200 mg QD · wk 48 · n 50NCT01384734 Phase 2, secondary
Lenacapavir (Sunlenca)204193 (B/F/TAF)—wk 54 · n 49NCT04143594 Phase 2, secondary
Maraviroc112.554.0+58.6QD · wk 48 · n 227NCT00098306 Phase 2/3, secondary
Raltegravir98.439.8+58.6400 mg b.i.d. · wk 48 · n 217NCT00293254 Phase 3, secondary
Rilpivirine2818.4 (CAR)—DTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797 Phase 3, secondary
Tenofovir alafenamide/emtricitabine6042 (Baseline Treatment Regimen (SBR))—wk 96 · n 959NCT01815736 Phase 3, secondary
Tipranavir4316 (Comparator Protease Inhibitor)—wk 48 · n 430NCT00144170 Phase 3, secondary

Drugs checked with no result here: 8 not posted, 8 not reported, 11 trial running.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 41 approved or late-stage drugs with a featured trial in HIV were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.